These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 2870354)

  • 41. The requirement of low calcium dialysate in patients on continuous ambulatory peritoneal dialysis receiving calcium carbonate as a phosphate binder.
    Cheng IK; Lu HB; Chan CY; Cheng SW; Robinson JD; Tam SC; Lo WK; Cheung WC
    Clin Nephrol; 1993 Aug; 40(2):100-5. PubMed ID: 8222365
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Long-term CaCO3 treatment of chronic hemodialysis patients: an attempt to prevent aluminum osteopathy.
    Matsubara M; Unagami H; Totsune K; Sato H; Kikuta Y; Ogawa M; Saito T; Yoshinaga K
    ASAIO Trans; 1988; 34(3):168-71. PubMed ID: 3196505
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Calcitriol pulse therapy for severe hyperparathyroidism or calcium salts as phosphate binders in renal dialysis patients?
    Gonella M; Calabrese G; Aleo AG; Vagelli G; Deambrogio P
    Nephron; 1995; 71(3):350-3. PubMed ID: 8569985
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Correction of high serum aluminium in a patient on maintenance haemodialysis.
    Wallace MR
    N Z Med J; 1981 May; 93(684):335-7. PubMed ID: 6942294
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Safety of new phosphate binders for chronic renal failure.
    Loghman-Adham M
    Drug Saf; 2003; 26(15):1093-115. PubMed ID: 14640773
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Evidence of increased parathyroid activity on discontinuation of high-aluminum dialysate in patients undergoing hemodialysis.
    O'Hare JA; Murnaghan DJ
    Am J Med; 1984 Aug; 77(2):229-32. PubMed ID: 6431809
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparison between different dialysate calcium concentrations in nocturnal hemodialysis.
    Toussaint ND; Polkinghorne KR; Kerr PG; Somerville CA; Agar JW
    Hemodial Int; 2007 Apr; 11(2):217-24. PubMed ID: 17403174
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Dialysate calcium reduction in CAPD patients treated with calcium carbonate and alfacalcidol.
    Cunningham J; Beer J; Coldwell RD; Noonan K; Sawyer N; Makin HL
    Nephrol Dial Transplant; 1992; 7(1):63-8. PubMed ID: 1316583
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Newcastle bone disease in Hong Kong: a study of aluminum associated osteomalacia.
    Chan MK; Varghese Z; Li MK; Wong WS; Li CS
    Int J Artif Organs; 1990 Mar; 13(3):162-8. PubMed ID: 2189835
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Compounds in development to combat hyperphosphataemia.
    Ritz E; Hergesell O
    Expert Opin Investig Drugs; 2001 Dec; 10(12):2185-90. PubMed ID: 11772314
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The effect of plasma phosphate on the action of 1alphaOHD3 in haemodialysis patients.
    Peacock M; Davison AM; Walker GS
    Adv Exp Med Biol; 1977; 81():559-69. PubMed ID: 899940
    [No Abstract]   [Full Text] [Related]  

  • 52. The influence of aluminium on parathyroid hormone levels in haemodialysis patients.
    Cannata JB; Briggs JD; Junor BJ; Beastall G; Fell GS
    Proc Eur Dial Transplant Assoc; 1983; 19():244-7. PubMed ID: 6878239
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Aluminum accumulation during treatment with aluminum hydroxide and dialysis in children and young adults with chronic renal disease.
    Salusky IB; Foley J; Nelson P; Goodman WG
    N Engl J Med; 1991 Feb; 324(8):527-31. PubMed ID: 1992306
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of gastric acid suppression with pantoprazole on the efficacy of calcium carbonate as a phosphate binder in haemodialysis patients.
    Cervelli MJ; Shaman A; Meade A; Carroll R; McDonald SP
    Nephrology (Carlton); 2012 Jul; 17(5):458-65. PubMed ID: 22471559
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Satisfactory control of secondary hyperparathyroidism with low-calcium dialysate in patients not receiving vitamin D.
    Teruel JL; Nitvarro JF; Marcen R; Aguilera A; Tato A; Ottuño J
    Miner Electrolyte Metab; 1997; 23(1):19-24. PubMed ID: 9058365
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Aluminium hydroxide versus sucralfate as a phosphate binder in uraemia.
    Leung AC; Henderson IS; Halls DJ; Dobbie JW
    Br Med J (Clin Res Ed); 1983 Apr; 286(6375):1379-81. PubMed ID: 6404468
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Relationship between the serum parathyroid hormone and magnesium levels in continuous ambulatory peritoneal dialysis (CAPD) patients using low-magnesium peritoneal dialysate.
    Cho MS; Lee KS; Lee YK; Ma SK; Ko JH; Kim SW; Kim NH; Choi KC
    Korean J Intern Med; 2002 Jun; 17(2):114-21. PubMed ID: 12164088
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Management of hyperphosphataemia in dialysis patients: role of phosphate binders in the elderly.
    Lorenzo Sellares V; Torres Ramírez A
    Drugs Aging; 2004; 21(3):153-65. PubMed ID: 14979734
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effect of CAPD and hemodialysis on parathyroid function.
    Malberti F; Corradi B; Imbasciati E
    Adv Perit Dial; 1996; 12():239-44. PubMed ID: 8865912
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effect of hypermagnesemia on circulating plasma parathyroid hormone in patients on regular hemodialysis therapy.
    McGonigle RJ; Weston MJ; Keenan J; Jackson DB; Parsons V
    Magnesium; 1984; 3(1):1-7. PubMed ID: 6482508
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.